Joseph Stevenson, DO
Cardiovascular Disease · Reno, NVNPI 1467444901
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $181,821 of the $222,255 with a category attached, or 81.8%. 44 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 40.7% of the total. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 780 payments — averaging $284.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$90K
- United Therapeutics Corporation$53K
- Boehringer Ingelheim$26K
- Lilly USA, LLC$23K
- Merck$18K
- Angiodynamics, Inc.$2K
- plus $10K from 38 others
Across 44 payments — averaging $3193.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$90K
- Actelion Pharmaceuticals, Ltd$45K
- United Therapeutics Corporation$6K
What the payments were for
- Consulting fees$3,4202%
- Speaking & faculty fees$181,82182%
- Travel & lodging$15,8627%
- Food & beverage$19,0349%
- Education$2170%
- Other$1,9021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$82,289
- OPSUMIT$75,074
- JARDIANCE$48,394
- TYVASO$20,304
- ORENITRAM$19,915
- REMODULIN$11,984
- WINREVAIR$10,957
- VenaCure 1470 Pro$1,902
- SAPIEN 3 Ultra RESILIA$371
- Ozempic$333
- TRELEGY ELLIPTA$218
- ZIO XT Patch$159
- MitraClip$145
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$136
- Mitra Clip system$130
- FARXIGA$125
- AMVUTTRA$125
- Vascepa$124
- Kerendia$123
- ZAVZPRET$122
How this compares
$222,255 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 316 | $3,964,108 |
| AdempasRiociguat | 227 | $3,088,907 |
| Tyvaso DpiTreprostinil | 68 | $1,615,837 |
| UptraviSelexipag | 60 | $1,365,782 |
| Orenitram ErTreprostinil Diolamine | 69 | $1,031,570 |
| EliquisApixaban | 392 | $468,365 |
| Ambrisentan | 155 | $341,767 |
| Tadalafil | 309 | $296,543 |
| OpsynviMacitentan/Tadalafil | 21 | $266,234 |
| JardianceEmpagliflozin | 200 | $241,973 |
| XareltoRivaroxaban | 111 | $167,855 |
| EntrestoSacubitril/Valsartan | 72 | $110,042 |
| Repatha SureclickEvolocumab | 142 | $109,517 |
| RemodulinTreprostinil Sodium | 20 | $73,744 |
| Praluent PenAlirocumab | 66 | $36,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $90,382 | $5,596,125397 claims |
| BayerAdempas | $650 | $3,088,907227 claims |
| PfizerEliquis | $611 | $468,365392 claims |
| Boehringer IngelheimJardiance | $26,279 | $241,973200 claims |
| Johnson & JohnsonXarelto | $1,085 | $167,855111 claims |
| NovartisEntresto | $1,120 | $110,04272 claims |
| United Therapeutics CorporationRemodulin | $52,904 | $73,74420 claims |
| Lilly USA, LLCMounjaro | $23,123 | $30,25421 claims |
| AstraZenecaFarxiga | $657 | $24,07624 claims |
| Esperion Therapeutics, Inc.Nexlizet | $367 | $13,01514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 cardiovascular disease providers in Nevada.
Other cardiovascular disease in Reno
- Thomas-Duythuc ToReno$339K
- Jay MasonReno$227K
- Devang DesaiReno$206K
- Christopher RowanReno$48K
- Ram ChallapalliReno$18K
- Anita KediaReno$9K
- Sridevi ChallapalliReno$8K
- Christopher WilsonReno$7K
- Arjun GururajLas Vegas$399K
- Branavan UmakanthanLas Vegas$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.